- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Grants Keytruda Priority Review to Treat Most Common Form of Liver Cancer
The FDA has granted priority review for Keytruda (pembrolizumab) as a treatment for previously treated patients with advanced hepatocellular carcinoma (HCC).
The FDA has granted priority review for Keytruda (pembrolizumab) as a treatment for previously treated patients with advanced hepatocellular carcinoma (HCC). The supplemental Biologics Application (sBLA) is also seeking accelerated approval for the new indication.
HCC is the most common type of liver cancer in adults. In the United States, it is estimated that 42,200 new cases of liver cancer will be diagnosed this year, and the incidence has nearly tripled since 1980. HCC has one of the highest mortality rates of solid cancers, with a 5-year survival rate of less than 15%.
The sBLA was submitted based on data from the phase 2 KEYNOTE-224 trial which were recently presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting. KEYNOTE-224 is a non-randomized, multicenter, open label, phase 2 trial that investigated the efficacy and safety of Keytruda in patients with advanced HCC.
“There continues to be a significant need for new options in the treatment of advanced hepatocellular carcinoma, which is the most common type of liver cancer,” said Scot Ebbinghaus, MD, in a statement. The drug is currently undergoing further assessment in 2 phase 3 randomized trials as a second-line treatment in patients with HCC.
The trial enrolled 104 patients and recorded an objective response in 18 patients (17%; 95% CI:11-26). The best overall responses were 1 patient (1%) that achieved complete response, and 17 (16%) that achieved partial responses. The study saw treatment-related adverse events occur in 76 (73%) of patients, with 16 (15%) being serious.
“The data supporting our application provide a clear rationale for the advancement of the Keytruda clinical program for hepatocellular carcinoma, and we are grateful for the opportunity to work with the FDA to potentially bring Keytruda to patients living with this difficult-to-treat cancer.”
Merck, the developer of Keytruda, is investigating the use of the drug in the treatment of gastrointestinal cancers in more than 10 different trials. The FDA has set a target action date of November 9, 2018.
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Combatting Misconceptions of Clinical Trials to Improve Patient Participation
October 16th 2024There are many misconceptions patients might have about clinical trials that prevent them from participating, and it’s important to understand what they are in order to overcome them, said Terry L. Keys, of University of Kentucky Markey Cancer Center.
Read More
Creating Equitable Cancer Care for Americans of Asian and Pacific Islander Heritage
October 15th 2024Naoto T. Ueno, MD, PhD, FACP, of the University of Hawai’I Cancer Center outlines the underrepresentation in clinical trials, the lack of permanent medical oncologists, and issues of trust affecting care for the populations living in Hawaii.
Read More
